Table 7 Studies evaluating sFLT
From: Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review
Study | Year | N | Population | Standard criteria for SIRS/sepsis | Association with sepsis | Other outcomes |
|---|---|---|---|---|---|---|
Schuetz et al., [52] | 2011 | 161 | Patients with hypotension: 69 sepsis, 35 cardiac, 12 hemorrhagic, 12 unknown | Clinical classification based on clinical and microbiological data | sFlt-1 higher in sepsis compared to non-sepsis (P < 0.05) SFlt-1 independently associated with sepsis after adjustment for age, sex, blood pressure and mortality (P = 0.03) with AUC 0.70 for discrimination of sepsis from non-sepsis | Â |
Shapiro et al., [77] | 2008 | 83 | ED patients with septic shock (17), suspected infection without shock (66), and non-infected controls | Suspected infection based on treating clinician | sFLT levels elevated with worsening disease: non-infected, suspected infection without shock, septic shock (159, 386 and 551 ng/dL, respectively, P < 0.01) | sFLT correlated with APACHE-II, SOFA scores upon presentation and at 24 h (P < 0.05 for all) |
Shapiro et al., [51] | 2010 | 221 | ED patients with sepsis without organ dysfunction (71), severe sepsis without shock (66), septic shock (71), and non-infected controls (13) | 1992 ACCP/SCCM [1] | sFLT levels elevated in septic shock compared with non-infected controls (243 vs 41 ng/ml, P < 0.001) | sFLT correlated with SOFA, APACHE-II, lactate; Predicted severe sepsis and mortality (AUC of 0.82 (95% CI 0.76 to 0.88), 0.91 (95% CI 0.87 to 0.95)) |